Back to search results

J147 for Acute Ischemic Stroke

This study is looking at a drug called J147 to see if it can help people who have had an acute ischemic stroke (a stroke caused by a blood clot). Researchers want to know if J147 is safe and if it improves recovery when given after a procedure to remove the clot. You might be able to join if you are between 18 and 90 years old, have had a recent stroke, and meet certain other health criteria. The study will compare people who receive J147 to those who receive a placebo (an inactive substance). Success will be measured by how safe J147 is over 90 days after treatment. The current status of this study is unclear.

Study design
This is an interventional study with 196 planned participants. It is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either J147 or a placebo, and neither you nor your doctors will know which you are receiving.
What's involved
You would undergo a series of three to four MRI brain scans and have blood samples collected at several times. You will also have evaluations to measure brain function.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored from enrollment until the end of the study at 90 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07430917

Safety and Efficacy of J147 in Acute Ischemic Stroke

Recruiting
PHASE2Ages 18–90InterventionalTreatment
Abrexa Pharmaceuticals, Inc.
~196 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:J147 Emulsion for InjectionPlacebo

At a glance

Recruiting sites
1 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of J147 Emulsion for Injection (J147) when administered with endovascular therapy in acute ischemic stroke patients.
Measured over From enrollment to end of study at 90 days.

Conditions

Acute Ischemic Stroke

Explore related trials

Acute Ischemic Stroke

NCT07430917

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Dell Seton Medical Center at the University of Texas at Austin

    Austin, Texasstudy coordinator listed

    Not yet recruiting

  • Javon Bea Hospital

    Rockford, Illinoisstudy coordinator listed

    Recruiting

  • Albany Medical Center

    Albany, New Yorkno site contact published

    Active, not recruiting

  • MemorialCare Long Beach Medical Center

    Long Beach, Californiano site contact published

    Active, not recruiting

  • Oregon Health and Science University

    Portland, Oregonno site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Marguerite Prior, Ph.D. · STUDY_DIRECTOR · Abrexa Pharmaceuticals, Inc.
  • Steven J Warach, MD, PhD · PRINCIPAL_INVESTIGATOR · Dell Seton Medical Center at the University of Texas at Austin

Who to contact

Marguerite Prior, Ph.D.
[email protected]
619-278-9516
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed informed consent obtained from the patient or legally authorized representative.
A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
Baseline NIHSS ≥5 and ≤25 points obtained prior to randomization with a disabling neurological deficit as determined by clinical judgement.
Pre-stroke mRS score of 0-2.
Availability to be treated within 24 hours of last known well.
Candidates to receive EVT treatment without IV thrombolytic therapy. Such patients should be initiated as recommended by the local standard of care for the early management of patients with AIS.
eTICI or better reperfusion achieved after completion of EVT.
Females, unless they are permanently sterile (e.g., hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or postmenopausal (defined as no menses for at least 12 consecutive months without an alternative medical cause and, when applicable, confirmed by serum follicle stimulating hormone \[FSH\] level) must agree to use highly effective methods of contraception during the study and for a minimum of 30 days after the last dose of study drug. In women aged \<45 years who report being postmenopausal, postmenopausal status must be confirmed by a serum FSH level in the postmenopausal range according to the laboratory's reference values. Until postmenopausal status is confirmed, these participants must remain abstinent or use a highly effective method of contraception. Highly effective methods include:
Women of childbearing potential (WOCBP) must have a negative urine pregnancy test before enrollment.
Male participants with WOCBP partners must either:
Men must also agree not to donate sperm during the study and for the same period post-treatment.
Occlusion of an internal carotid, middle cerebral, anterior cerebral, posterior cerebral artery, suitable for mechanical embolectomy, confirmed on vascular imaging. Tandem extra-intracranial lesions may be included.
MRI criterion: volume of DWI ≥5 and ≤70 mL determined by any validated, automated artificial intelligence (AI) thresholding estimates of core and penumbra for participant selection and mismatch volume at least 25 mL, mismatch ratio at least 1.8 and a hypoperfusion intensity ratio 0.4 or higher.

Exclusion

Absolute contraindication to MRI with gadolinium contrast.
Serious, advanced, or terminal illness with an anticipated life expectancy of \<6 months.
History of life-threatening allergy (more than rash) to contrast medium.
Known renal insufficiency with creatinine ≥3 mg/dL or glomerular filtration rate (GFR) of \<30 mL/min.
Clinically significant hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3× upper level of normal (ULN) and/or total bilirubin \>1.5× ULN, unless attributable to a known diagnosis of Gilbert's syndrome without other evidence of liver dysfunction.
Patients that have received intravenous or intra-arterial thrombolytic for the current stroke prior to mechanical thrombectomy.
Patients participating in a study involving an investigational drug or device.
Any clinically significant medical history, physical examination finding, laboratory abnormality, vital sign abnormality, or 12-Lead ECG finding that, in the opinion of the investigator, may pose a risk to the patient's safety or well-being, interfere with the patient's ability to participate fully in the study, or confound the interpretation of study results.
Patients that are unlikely to be available for a 90-day follow up.
Female patients who are pregnant or lactating or are unwilling to use effective methods of contraception.
Patients with known adverse reaction to J147 or its components.
Computed tomography (CT) or MRI evidence of acute intracranial hemorrhage (the presence of chronic microbleeds is allowed).
Significant mass effect with midline shift.
Imaging evidence or history of intracranial neoplasms except for meningiomas.

What this trial measures

  • Safety of J147 Emulsion for Injection (J147) when administered with endovascular therapy in acute ischemic stroke patients.From enrollment to end of study at 90 days.

    Continuous vital signs, 12-Lead ECG, and laboratory assessments will be summarized using descriptive statistics, which includes count, mean, median, standard deviation, min and max by treatment arm and visits. Incidence and severity of adverse events and serious adverse events will be summarized with count and percentages by treatment arm, overall and by System Organ Class and Preferred Term. Deaths will be listed.